Phase 1 Study of Combination Treatment with PTK 787/ZK 222584 and Cetuximab for Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics Analysis

INTRODUCTION: PTK/ZK is a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors, platelet-derived growth factor receptor, colony-stimulating factor 1 receptor, and cytokine stem cell factor receptor. Cetuximab is a monoclonal antibody against epidermal growth fact...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Langenberg, Marlies HG, Witteveen, Petronella O, Lankheet, Nienke AG, Roodhart, Jeanine ML, Rosing, Hilde, van den Heuvel, Ingeborg JGM, Beijnen, Jos H, Voest, Emile E
Materialtyp: Artigo
Språk:Inglês
Publicerad: Neoplasia Press Inc. 2010
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2814358/
https://ncbi.nlm.nih.gov/pubmed/20126478
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk